Whole blood gene expression can distinguish benign from malignant lung nodules transitioning from microarrays to a nanostring platform

Development of a non-invasive, whole blood microarray gene expression signature that accurately distinguishes malignant from benign lung nodules detected by LDCT and the successful transition of that signature to a custom NanoString panel with no loss of accuracy. Whole blood gene expression from patients with malignant (MN) and benign (BN) nodules